Year of investment: 2017
TripleMed is developing minimally invasive products against aneurysms, without the need for incisions. The first product fills the aneurysm and prevents blood from entering, whilst leaving a channel for the blood to flow through to reach the other arteries. This enables a better and longer-lasting solution to the problem of aortic aneurysms.
For more information on the company and product(s), please refer to the following video:
Year of investment: 2016
Year of investment: 2016
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a US subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
Year of investment: 2014
Enzypep developed a breakthrough technology for the synthesis of peptides using enzymes. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner.
Year of investment: 2014
Cristal Therapeutics (formerly known as Cristal Delivery) is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies, registered as CriPec®. Cristal Therapeutic’s mission is optimize the therapeutic performance of drugs and thereby improve patient care.
Year of investment: 2012
BioActor develops and markets proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements.
BioActor focuses on the development of proprietary bioactives with human clinical evidence that address health concerns related to metabolic syndrome and ageing such as diabetes, osteoporosis and cardiovascular disease.
For more information on the company and product(s), please refer to the following video:
Year of investment: 2011
ACS Biomarker targets discovery and validation of novel miRNA and protein-based cardiovascular biomarkers, improving diagnoses and management of cardiac diseases. ACS Biomarker licensed out exclusive rights to BG Medicine on its biomarker Galectin-3 as a prognostic indicator of congestive heart failure.
Year of investment: 2011
Q Chip, based in Cardiff (Wales, UK) commercializes innovative sustained-release drug formulations of injectable therapeutics. The sustained- release can be tailored and administration of the therapeutics is improved. The company was acquired by Midatech Pharma plc in late 2014.
Year of investment: 2011
Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI). N4I’s products MRWire and MagnaFy are used for navigation to treat cardiovascular diseases and for radiotherapy.
For more information on the company and product(s), please refer to the following video:
Year of investment: 2010
CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company has facilities in Marseille (France) and at the Chemelot Campus.